Review ArticleReview Article
Open Access

Combining antiangiogenic therapy and radiation in nasopharyngeal carcinoma

Zhuo Chen and Xin-Hua Xu
Saudi Medical Journal June 2015, 36 (6) 659-664; DOI: https://doi.org/10.15537/smj.2015.6.11460

References

  1. ↵
    1. Ji X,
    2. Xie C,
    3. Hu D,
    4. Fan X,
    5. Zhou Y,
    6. Zheng Y
    (2013) Survival benefit of adding chemotherapy to intensity modulated radiation in patients with locoregionally advanced nasopharyngeal carcinoma. PLoS One 8:e56208.
    OpenUrl
  2. ↵
    1. Komatsu M,
    2. Tsukuda M,
    3. Matsuda H,
    4. Horiuchi C,
    5. Taguch T,
    6. Takahashi M,
    7. et al.
    (2012) Comparison of concurrent chemoradiotherapy versus induction chemotherapy followed by radiation in patients with nasopharyngeal carcinoma. Anticancer Res 32:681–686.
    OpenUrlAbstract/FREE Full Text
  3. ↵
    1. Wu Y,
    2. Zheng Y,
    3. Shen Z,
    4. Ge W,
    5. Xie Y,
    6. Li C
    (2014) Endostar combined with radiotherapy increases radiation sensitivity by decreasing the expression of TGF-β1, HIF-1α and bFGF. Exp Ther Med 79:911–916.
    OpenUrl
  4. ↵
    1. Karar J,
    2. Maity A
    (2009) Modulating the tumor microenvironment to increase radiation responsiveness. Cancer Biol Ther 8:1994–2001.
    OpenUrlCrossRefPubMedWeb of Science
  5. ↵
    1. Yeom CJ,
    2. Zeng L,
    3. Zhu Y,
    4. Hiraoka M,
    5. Harada H
    (2011) Strategies to assess hypoxic /HIF-1-active cancer cells for the development of innovative radiation therapy. Cancers (Basel) 3:3610–3631.
    OpenUrl
  6. ↵
    1. Shi D,
    2. Xie F,
    3. Zhang Y,
    4. Tian Y,
    5. Chen W,
    6. Fu L,
    7. et al.
    (2013) TFAP2A Regulates Nasopharyngeal Carcinoma Growth and Survival by Targeting HIF-1a Signaling Pathway. Cancer Prev Res 7:266–277.
    OpenUrl
  7. ↵
    1. Shi D,
    2. Guo W,
    3. Chen W,
    4. Fu L,
    5. Wang J,
    6. Tian Y,
    7. et al.
    (2012) Nicotine promotes proliferation of human nasopharyngeal carcinoma cells by regulating a7AChR, ERK, HIF-1a and VEGF/PEDF signaling. PLOS One 7:e43898.
    OpenUrlPubMed
  8. ↵
    1. Khong TL,
    2. Thairu N,
    3. Larsen H,
    4. Dawson PM,
    5. Kiriakidis S,
    6. Paleolog EM
    (2013) Identification of the angiogenic gene signature induced by EGF and hypoxia in colorectal cancer. BMC Cancer 13:518.
    OpenUrlCrossRefPubMed
  9. ↵
    1. Choi SH,
    2. Kwon OJ,
    3. Park JY,
    4. Kim do Y,
    5. Ahn SH,
    6. Kim SU,
    7. et al.
    (2014) Inhibition of tumour angiogenesis and growth by small hairpin HIF-1a and IL-8 in hepatocellular carcinoma. Liver Int 34:632–642.
    OpenUrlPubMed
  10. ↵
    1. Shi D,
    2. Xie F,
    3. Zhang Y,
    4. Tian Y,
    5. Chen W,
    6. Fu L,
    7. et al.
    (2014) TFAP2A regulates nasopharyngeal carcinoma growth and survival by targeting HIF-1a signaling pathway. Cancer Prev Res (Phila) 7:266–277.
    OpenUrlAbstract/FREE Full Text
  11. ↵
    1. Chen Y,
    2. Li X,
    3. Wu S,
    4. Xu G,
    5. Zhou Y,
    6. Gong L,
    7. et al.
    (2014) Expression of HIF-1a and CAIX in nasopharyngeal carcinoma and their correlation with patients’ prognosis. Med Oncol 31:304.
    OpenUrl
  12. ↵
    1. Wan XB,
    2. Fan XJ,
    3. Chen MY,
    4. Xiang J,
    5. Huang PY,
    6. Guo L,
    7. et al.
    (2010) Elevated Beclin 1 expression is correlated with HIF-1alpha in predicting poor prognosis of nasopharyngeal carcinoma. Autophagy 6:395–404.
    OpenUrlCrossRefPubMed
  13. ↵
    1. Shou Z,
    2. Lin L,
    3. Liang J,
    4. Li JL,
    5. Chen HY
    (2012) Expression and prognosis of FOXO3a and HIF-1a in nasopharyngeal carcinoma. J Cancer Res Clin Oncol 138:585–593.
    OpenUrlPubMed
  14. ↵
    1. Zhong Q,
    2. Wang S,
    3. Li C,
    4. Yang C,
    5. Lin X,
    6. Lin X,
    7. et al.
    (2014) [Expressions and correlation of HPA, CK2beta and HIF-1alpha in nasopharyngeal carcinoma]. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 28:157–161, Chinese.
    OpenUrl
  15. ↵
    1. Khan Z,
    2. Khan N,
    3. Tiwari RP,
    4. Patro IK,
    5. Prasad GB,
    6. Bisen PS
    (2010) Down-regulation of survivin by oxaliplatin diminishes radioresistance of head and neck squamous carcinoma cells. Radiother Oncol 96:267–273.
    OpenUrlCrossRefPubMed
  16. ↵
    1. Hosokawa Y,
    2. Okumura K,
    3. Terashima S,
    4. Sakakura Y
    (2012) Radiation protective effect of hypoxia-inducible factor-1a (HIF-1a) on human oral squamous cell carcinoma cell lines. Radiat Prot Dosimetry 152:159–163.
    OpenUrlCrossRefPubMed
  17. ↵
    1. Xu P,
    2. Huang JM,
    3. Ren Y,
    4. Zha X,
    5. Deng BF,
    6. Wu JH,
    7. et al.
    (2010) Regulation of hypoxia-induced mRNA expressions of HIF-1alpha and osteopontin and in vitro radiosensitization by tirapazamine in human nasopharyngeal carcinoma HNE-1 and CNE-1 cells. Chin J Cancer 29:126–130.
    OpenUrlPubMed
  18. ↵
    1. Chen YH,
    2. Pan SL,
    3. Wang JC,
    4. Kuo SH,
    5. Cheng JC,
    6. Teng CM
    (2014) Radiation-induced VEGF-C expression and endothelial cell proliferation in lung cancer. Strahlenther Onkol 190:1154–1162.
    OpenUrl
  19. ↵
    1. Yu H,
    2. Mohan S,
    3. Natarajan M
    (2012) Radiation-triggered NF-kB activation is responsible for the angiogenic signaling pathway and neovascularization for breast cancer cell proliferation and growth. Breast Cancer (Auckl) 6:125–135.
    OpenUrlPubMed
  20. ↵
    1. Erkal EY,
    2. Bora H,
    3. Tepeoğlu M,
    4. Akmansu M
    (2014) Role of vascular endothelial growth factor in clinically localized prostate cancer treated with radiation therapy. Balkan Med J 31:43–49.
    OpenUrl
  21. ↵
    1. Moeller BJ,
    2. Dewhirst MW
    (2006) HIF-1 and tumour radiosensitivity. Br J Cancer 95:1–5.
    OpenUrlCrossRefPubMedWeb of Science
  22. ↵
    1. Chen C,
    2. Yu Z
    (2009) siRNA targeting HIF-1a induces apoptosis of pancreatic cancer Cells through NF-κB-independent and dependent pathways under hypoxic conditions. Anticancer Res 29:1367–1372.
    OpenUrlAbstract/FREE Full Text
  23. ↵
    1. Sendoel A,
    2. Kohler I,
    3. Fellmann C,
    4. Lowe SW,
    5. Hengartner MO
    (2010) HIF-1 antagonizes p53-mediated apoptosis through a secreted neuronal tyrosinase. Nature 465:577–583.
    OpenUrlCrossRefPubMedWeb of Science
  24. ↵
    1. Oike T,
    2. Suzuki Y,
    3. Al-Jahdari W,
    4. Mobaraki A,
    5. Saitoh JI,
    6. Torikai K,
    7. et al.
    (2012) Suppression of HIF-1a expression and radiation resistance in acute hypoxic conditions. Exp Ther Med 3:141–145.
    OpenUrlPubMed
  25. ↵
    1. Kim YH,
    2. Yoo KC,
    3. Cui YH,
    4. Uddin N,
    5. Lim EJ,
    6. Kim MJ,
    7. et al.
    (2014) Radiation promotes malignant progression of glioma cells through HIF-1alpha stabilization. Cancer Lett 354:132–141.
    OpenUrl
  26. ↵
    1. Zhang R,
    2. Zhao Y,
    3. Zhang S,
    4. Lv J
    (2013) [The expressions of EphrinB2 and VEGF in nasopharyngeal carcinoma and their clinical significance]. Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 27:178–180, Chinese.
    OpenUrl
  27. ↵
    1. Dorsey K,
    2. Agulnik M
    (2013) Promising new molecular targeted therapies in head and neck cancer. Drugs 73:315–325.
    OpenUrlCrossRefPubMedWeb of Science
  28. ↵
    1. Li WW,
    2. Long GX,
    3. Liu DB,
    4. Mei Q,
    5. Wang JF,
    6. Hu GY,
    7. et al.
    (2014) Cyclooxygenase-2 inhibitor celecoxib suppresses invasion and migration of nasopharyngeal carcinoma cell lines through a decrease in matrix metalloproteinase-2 and -9 activity. Pharmazie 69:132–137.
    OpenUrlPubMedWeb of Science
  29. ↵
    1. Li XY,
    2. Lin YC,
    3. Huang WL,
    4. Hong CQ,
    5. Chen JY,
    6. You YJ,
    7. et al.
    (2012) Zoledronic acid inhibits proliferation and impairs migration and invasion through downregulating VEGF and MMPs expression in human nasopharyngeal carcinoma cells. Med Oncol 29:714–720.
    OpenUrlPubMed
  30. ↵
    1. Chen HH,
    2. Weng BQ,
    3. Cheng KJ,
    4. Liu HY,
    5. Wang SQ,
    6. Lu YY
    (2014) Effect of the vascular endothelial growth factor expression level on angiopoietin-2 mediated nasopharyngeal carcinoma growth. Vasc Cell 6:4.
    OpenUrl
  31. ↵
    1. Chen J,
    2. Ran Y,
    3. Hong C,
    4. Chen Z,
    5. You Y
    (2010) Anti-cancer effects of celecoxib on nasopharyngeal carcinoma HNE-1 cells expressing COX-2 oncoprotein. Cytotechnology 62:431–438.
    OpenUrlPubMed
  32. ↵
    1. Argiris A,
    2. Kotsakis AP,
    3. Hoang T,
    4. Worden FP,
    5. Savvides P,
    6. Gibson MK,
    7. et al.
    (2013) Cetuximab and bevacizumab: preclinical data and phase II trial in recurrent or metastatic squamous cell carcinoma of the head and neck. Ann Oncol 24:220–225.
    OpenUrlCrossRefPubMedWeb of Science
  33. ↵
    1. Bozec A,
    2. Sudaka A,
    3. Fischel JL,
    4. Brunstein MC,
    5. Etienne-Grimaldi MC,
    6. Milano G
    (2008) Combined effects of bevacizumab with erlotinib and irradiation: a preclinical study on a head and neck cancer orthotopic model. Br J Cancer 99:93–99.
    OpenUrlCrossRefPubMedWeb of Science
  34. ↵
    1. Lee NY,
    2. Zhang Q,
    3. Pfister DG,
    4. Kim J,
    5. Garden AS,
    6. Mechalakos J,
    7. et al.
    (2012) Addition of bevacizumab to standard chemoradiation for locoregionally advanced nasopharyngeal carcinoma(RTOG 0615):a phase 2 multi-institutional trial. Lancet Oncol 13:172–180.
    OpenUrlCrossRefPubMedWeb of Science
  35. ↵
    1. Elser C,
    2. Siu LL,
    3. Winquist E,
    4. Agulnik M,
    5. Pond GR,
    6. Chin SF,
    7. et al.
    (2007) Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma. J Clin Oncol 25:3766–3773.
    OpenUrlAbstract/FREE Full Text
  36. ↵
    1. Yadav A,
    2. Kumar B,
    3. Teknos TN,
    4. Kumar P
    (2011) Sorafenib enhances the antitumor effects of chemoradiation treatment by downregulating ERCC-1 and XRCC-1DNA repair proteins. Mol Cancer Ther 10:1241–1251.
    OpenUrlAbstract/FREE Full Text
  37. ↵
    1. Xue C,
    2. Huang Y,
    3. Huang PY,
    4. Yu QT,
    5. Pan JJ,
    6. Liu LZ,
    7. et al.
    (2013) Phase II study of sorafenib in combination with cisplatin and 5-fluorouracil to treat recurrent or metastatic nasopharyngeal carcinoma. Ann Oncol 24:1055–1061.
    OpenUrlCrossRefPubMed
  38. ↵
    1. Huang Y,
    2. Wang Y,
    3. Li Y,
    4. Guo K,
    5. He Y
    (2011) Role of sorafenib and sunitinib in the induction of expressions of NKG2D ligands in nasopharyngeal carcinoma with high expression of ABCG2. J Cancer Res Clin Oncol 137:829–837.
    OpenUrlCrossRefPubMed
  39. ↵
    1. Wen QL,
    2. Meng MB,
    3. Yang B,
    4. Tu LL,
    5. Jia L,
    6. Zhou L,
    7. et al.
    (2009) Endostar, a recombined humanized endostatin, enhances the radio response for human nasopharyngeal carcinoma and human lung adenocarcinoma xenografts in mice. Cancer Sci 100:1510–1519.
    OpenUrlCrossRefPubMed
  40. ↵
    1. Zhou J,
    2. Wang L,
    3. Xu X,
    4. Tu Y,
    5. Qin S,
    6. Yin Y
    (2012) Antitumor activity of Endostar combined with radiation against human nasopharyngeal carcinoma in mouse xenograft models. Oncol Lett 4:976–980.
    OpenUrlPubMed
  41. ↵
    1. Zhou N,
    2. Hu G,
    3. Mei Q,
    4. Qiu H,
    5. Long G,
    6. Chen C,
    7. et al.
    (2011) Inhibitory effect of Endostar in combination with radiotherapy in a mouse model of human CNE2 nasopharyngeal carcinoma. J Huazhong Univ Sci Technolog Med Sci 31:62–66.
    OpenUrlPubMed
  42. ↵
    1. Peng F,
    2. Xu Z,
    3. Wang J,
    4. Chen Y,
    5. Li Q,
    6. Zuo Y,
    7. et al.
    (2012) Recombinant human endostatin normalizes tumor vasculature and enhances radiation response in xenografted human nasopharyngeal carcinoma models. PLoS One 7:e34646.
    OpenUrlPubMed
  43. ↵
    1. Jin T,
    2. Li B,
    3. Chen XZ
    (2013) A phase II trial of Endostar combined with gemcitabine and cisplatin chemotherapy in patients with metastatic nasopharyngeal carcinoma (NCT01612286). Oncol Res 21:317–323.
    OpenUrl
  44. ↵
    1. Ferrara N,
    2. Gerber HP,
    3. LeCouter J
    (2003) The biology of VEGF and its receptors. Nat Med 9:669–676.
    OpenUrlCrossRefPubMedWeb of Science
  45. ↵
    1. Wicki A,
    2. Wild D,
    3. Prêtre V,
    4. Mansi R,
    5. Orleth A,
    6. Reubi JC,
    7. et al.
    (2014) Synergism of peptide receptor-targeted Auger electron radiation therapy with anti-angiogenic compounds in a mouse model of neuroendocrine tumors. EJNMMI Res 4:9.
    OpenUrlCrossRefPubMed
  46. ↵
    1. Hsu HW,
    2. Wall NR,
    3. Hsueh CT,
    4. Kim S,
    5. Ferris RL,
    6. Chen CS,
    7. et al.
    (2014) Combination antiangiogenic therapy and radiation in head and neck cancers. Oral Oncol 50:19–26.
    OpenUrlCrossRefPubMed
  47. ↵
    1. Iversen AB,
    2. Busk M,
    3. Horsman MR
    (2013) Induction of hypoxia by vascular disrupting agents and the significance for their combination with radiation therapy. Acta Oncol 52:1320–1326.
    OpenUrlCrossRefPubMed
  48. ↵
    1. Liu Y,
    2. Liu Y,
    3. Sun C,
    4. Gan L,
    5. Zhang L,
    6. Mao A,
    7. et al.
    (2014) Carbon ion radiation inhibits glioma and endothelial cell migration induced by secreted VEGF. PLoS One 6:e98488.
    OpenUrl
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools
Bookmark this article

Jump to section